Back to Home

Real-World Data Licensing: A Large Opportunity for RegenMed

January 14, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Real-World Data Licensing: A Large Opportunity for RegenMed

June 9, 2025

The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth 1.  At the same time, there is a strong focus on the importance of real-world data.  Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends on an enterprise level.

Everyday physician-patient interactions — correlated to long-term outcomes — are the largest and best source of real world data.  In the US alone, over 1 billion such interactions take place each year at 7,400 hospitals, 9,600 ambulatory surgery centers and 340,000 physician group practices 2.    

Larger hospital systems are now monetizing their traditional electronic medical record data.  However, they are investing heavily to do so.  Moreover, the ownership, clinical significance, and reliability of EMR datasets are open to question.  

In contrast, Circles represent a clinical grade, low cost and highly efficient method to develop and monetize real-world datasets.  Circles datasets are generated through a patented and minimally burdensome closed system.  This enable the generation of healthcare datasets which are regularly updated, clinically significant, “hallucination” free, and protected from third-party claims of ownership.

Hospitals and other provider groups are facing strong financial headwinds.  Reimbursement rates are declining while costs are increasing.  EMR and other IT costs are failing to deliver the promised patient care or economic returns.  Circles generate a new and accumulating revenue source at a small fraction of typical IT expenditures.  

Moreover, Circles datasets lead to genuine value-based care, health equity, and deeper engagement with physicians and patients.  For RegenMed, proprietary and monetizable Circles datasets are the foundation of accelerating enterprise sales.

LEARN MORE

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Real-World Data Licensing: A Large Opportunity for RegenMed

January 14, 2025

The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth 1.  At the same time, there is a strong focus on the importance of real-world data.  Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends on an enterprise level.

Everyday physician-patient interactions — correlated to long-term outcomes — are the largest and best source of real world data.  In the US alone, over 1 billion such interactions take place each year at 7,400 hospitals, 9,600 ambulatory surgery centers and 340,000 physician group practices 2.    

Larger hospital systems are now monetizing their traditional electronic medical record data.  However, they are investing heavily to do so.  Moreover, the ownership, clinical significance, and reliability of EMR datasets are open to question.  

In contrast, Circles represent a clinical grade, low cost and highly efficient method to develop and monetize real-world datasets.  Circles datasets are generated through a patented and minimally burdensome closed system.  This enable the generation of healthcare datasets which are regularly updated, clinically significant, “hallucination” free, and protected from third-party claims of ownership.

Hospitals and other provider groups are facing strong financial headwinds.  Reimbursement rates are declining while costs are increasing.  EMR and other IT costs are failing to deliver the promised patient care or economic returns.  Circles generate a new and accumulating revenue source at a small fraction of typical IT expenditures.  

Moreover, Circles datasets lead to genuine value-based care, health equity, and deeper engagement with physicians and patients.  For RegenMed, proprietary and monetizable Circles datasets are the foundation of accelerating enterprise sales.

LEARN MORE

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

1 Healthcare Analytics Market Size, Share, and Trends 2024 to 2034  

2 How many hospitals are in the U.S.?; How many ambulatory surgery centers are in the U.S.?; Number of physician group practices by state

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.